AU2017264825B2 - CD200 mutant and its uses - Google Patents

CD200 mutant and its uses Download PDF

Info

Publication number
AU2017264825B2
AU2017264825B2 AU2017264825A AU2017264825A AU2017264825B2 AU 2017264825 B2 AU2017264825 B2 AU 2017264825B2 AU 2017264825 A AU2017264825 A AU 2017264825A AU 2017264825 A AU2017264825 A AU 2017264825A AU 2017264825 B2 AU2017264825 B2 AU 2017264825B2
Authority
AU
Australia
Prior art keywords
val
thr
leu
ser
lys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017264825A
Other languages
English (en)
Other versions
AU2017264825A1 (en
Inventor
Jonathan HEAL
Philip Huxley
Joseph SHERIDAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ducentis Biotherapeutics Ltd
Original Assignee
Ducentis Biotherapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ducentis Biotherapeutics Ltd filed Critical Ducentis Biotherapeutics Ltd
Publication of AU2017264825A1 publication Critical patent/AU2017264825A1/en
Application granted granted Critical
Publication of AU2017264825B2 publication Critical patent/AU2017264825B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62DNA sequences coding for fusion proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2017264825A 2016-05-10 2017-05-10 CD200 mutant and its uses Active AU2017264825B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1608197.8A GB201608197D0 (en) 2016-05-10 2016-05-10 Novel proteins
GB1608197.8 2016-05-10
PCT/GB2017/051303 WO2017194941A1 (en) 2016-05-10 2017-05-10 Cd200 mutant and its uses

Publications (2)

Publication Number Publication Date
AU2017264825A1 AU2017264825A1 (en) 2018-11-15
AU2017264825B2 true AU2017264825B2 (en) 2021-04-08

Family

ID=56297468

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017264825A Active AU2017264825B2 (en) 2016-05-10 2017-05-10 CD200 mutant and its uses

Country Status (15)

Country Link
US (1) US11203628B2 (https=)
EP (1) EP3455247A1 (https=)
JP (1) JP6997767B2 (https=)
KR (2) KR102498901B1 (https=)
CN (1) CN109219614B (https=)
AU (1) AU2017264825B2 (https=)
BR (1) BR112018073280A2 (https=)
CA (1) CA3023601A1 (https=)
EA (1) EA201892554A1 (https=)
GB (1) GB201608197D0 (https=)
IL (1) IL262846B2 (https=)
MX (1) MX386295B (https=)
SG (1) SG11201809677XA (https=)
WO (1) WO2017194941A1 (https=)
ZA (1) ZA201807079B (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201608197D0 (en) 2016-05-10 2016-06-22 Ducentis Biotherapeutics Ltd Novel proteins
KR102186780B1 (ko) 2019-02-18 2020-12-04 박주현 비행부와 탑승부를 분리하여 축으로 결합한 유인드론
CN110859951A (zh) * 2019-09-23 2020-03-06 中国药科大学 Cd200蛋白和cd200融合蛋白在制备治疗银屑病药物中的应用
GB202115803D0 (en) * 2021-11-03 2021-12-15 Ducentis Biotherapeutics Ltd Novel proteins
AU2023265174A1 (en) * 2022-05-06 2024-12-12 Ducentis Biotherapeutics Limited Novel cd200 fusion proteins
CN119365483A (zh) * 2022-05-06 2025-01-24 杜森蒂斯生物治疗有限公司 新型cd200融合蛋白
GB2626300A (en) * 2022-12-08 2024-07-24 Ducentis Biotherapeutics Ltd Mutated CD200 proteins and methods of use therof
GB202303291D0 (en) 2023-03-07 2023-04-19 Secr Defence Medicament and medicament combination for use in the treatment of infectious disease
GB202306711D0 (en) * 2023-05-05 2023-06-21 Ducentis Biotherapeutics Ltd Novel proteins
WO2025106841A1 (en) * 2023-11-15 2025-05-22 The University Of Chicago Methods and compositions for inducing antigen specific tolerance

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7223729B2 (en) 1997-11-07 2007-05-29 Trillium Therapeutics Inc. Methods of treating allergy by administering a CD200 protein
EP1032662B1 (en) * 1997-11-07 2006-03-08 Trillium Therapeutics Inc. Methods and compositions for immunomodulation
MXPA01010480A (es) * 1999-04-13 2002-03-27 Schering Corp Usos novedosos de la proteina 0x2 de mamifero y reactivos relacionados.
EP1261743A2 (en) * 2000-03-07 2002-12-04 Hyseq, Inc. Novel nucleic acids and polypeptides
CA2429579A1 (en) * 2000-11-22 2002-05-30 Trillium Therapeutics Inc. Truncated cd200
KR20130108481A (ko) * 2005-08-19 2013-10-02 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
AU2008206502A1 (en) * 2007-01-11 2008-07-24 Boehringer Ingelheim International Gmbh CD200 and its receptor, CD200R, modulate bone mass via the differentiation of osteoclasts
CN102448982B (zh) * 2009-03-31 2018-04-20 华盛顿大学 用于调节靶细胞上补体调节蛋白的活性的组合物和方法
CA2786692A1 (en) * 2010-01-11 2011-07-14 Alexion Pharmaceuticals, Inc. Biomarkers of immunomodulatory effects in humans treated with anti-cd200 antibodies
GB201608197D0 (en) 2016-05-10 2016-06-22 Ducentis Biotherapeutics Ltd Novel proteins

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HATHERLEY DEBORAH ET AL, "Structures of CD200/CD200 Receptor Family and Implications for Topology, Regulation, and Evolution", STRUCTURE (CAMBRIDGE), (2013-05), vol. 21, no. 5, ISSN 0969-2126, pages 820 - 832 *

Also Published As

Publication number Publication date
US11203628B2 (en) 2021-12-21
BR112018073280A2 (pt) 2019-03-19
EA201892554A1 (ru) 2019-04-30
US20190367580A1 (en) 2019-12-05
GB201608197D0 (en) 2016-06-22
CA3023601A1 (en) 2017-11-16
IL262846A (en) 2018-12-31
KR20230025937A (ko) 2023-02-23
IL262846B2 (en) 2023-02-01
KR102689460B1 (ko) 2024-07-26
NZ747665A (en) 2025-10-31
JP6997767B2 (ja) 2022-03-04
IL262846B (en) 2022-10-01
EP3455247A1 (en) 2019-03-20
KR102498901B1 (ko) 2023-02-10
AU2017264825A1 (en) 2018-11-15
SG11201809677XA (en) 2018-11-29
KR20190003761A (ko) 2019-01-09
CN109219614B (zh) 2022-05-24
CN109219614A (zh) 2019-01-15
ZA201807079B (en) 2019-07-31
MX2018013778A (es) 2019-08-01
WO2017194941A1 (en) 2017-11-16
JP2019518788A (ja) 2019-07-04
MX386295B (es) 2025-03-18

Similar Documents

Publication Publication Date Title
AU2017264825B2 (en) CD200 mutant and its uses
JP2021522835A (ja) 二機能性結合ポリペプチド
CN114901310A (zh) 使用il-2受体激动剂和免疫检查点抑制剂的组合疗法
TW202228790A (zh) 用於長效經眼遞送之非共價蛋白質-玻尿酸結合物
US20250026805A1 (en) Novel proteins
JP2025515191A (ja) 新規cd200融合タンパク質
JP2024544972A (ja) Sirp1a及びcd40lベースのキメラタンパク質
US20260116951A1 (en) Novel cd200 fusion proteins
US20260116946A1 (en) Novel cd200 fusion proteins
JP2025516364A (ja) 新規cd200融合タンパク質
CN102470157A (zh) 广谱erbb配体结合分子及其制备和使用方法
EA042608B1 (ru) Мутант cd200 и его применения
US20230272026A1 (en) A fusion protein comprising an antigen binding domain and a cytokine trimer domain
EP4705332A1 (en) Cd200 fusion proteins
CN116761634A (zh) 用于长效眼部递送的非共价蛋白质-透明质酸缀合物

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)